



## Company Overview

Heat Biologics is a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

## Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open Today

May 3 2022, 7:00 AM EDT

## Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

Apr 27 2022, 8:00 AM EDT

## Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics

Apr 20 2022, 8:00 AM EDT

## Stock Overview

Symbol	HTBX
Exchange	NYSE American
Market Cap	
Last Price	\$
52-Week	\$ - \$

## Investor Relations

[investorrelations@heatbio.com](mailto:investorrelations@heatbio.com)

## Management Team

### Jeffrey Wolf

Founder, Chairman and CEO

### George Peoples, M.D., FACS

Chief Medical Advisor

### Anthony Manning, Ph.D.

Chief Scientific Advisor

### William L. Ostrander

Chief Financial Officer

### Paul W. Tebbey, Ph.D., M.B.A.

Senior Vice President of Product Development and Portfolio Strategy

### Guillermo (Bill) Arana, MS

Vice President of Clinical Operations

### Matthew M. Seavey, Ph.D.

Vice President of Research

### Cheni Kwok, Ph.D., CLP

Senior Business Development Advisor

## Heat Biologics, Inc.

627 Davis Drive  
Suite 400  
Morrisville, NC 27560

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.